Vendor Intelligence Report: Liberty Peptides

Published 13 Jun 2026. 21-page investigative report on who is behind Liberty Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Liberty Peptides is a product-specific bet, not a clean vendor-wide pass. Across 19 Finnrick lab tests, Liberty Peptides has 7 passes and 12 failures, for an overall pass rate of 37%. The signal is uneven: Semaglutide is the comparatively better-supported peptide in the current record, while BPC-157 and CJC-1295 are the clear weak spots, with no passing independent samples in this set. The full report also shows how some ratings become fragile under stricter grading.

The business record raises a different kind of risk. Formation records and archived site captures do not line up cleanly: the storefront was active before the Delaware LLC existed, and the entity record reviewed for the report was not in good standing. Liberty’s site also leans on domestic-manufacturing language, but the investigation did not identify a U.S. plant, cleanroom, or manufacturing operator behind that claim.

The quality-documentation trail is not reassuring enough to close the gap. Liberty COAs route through Horizon Analytical; the reviewed materials found no ISO 17025 accreditation claim and show vendor-overlap signals involving Direct Peptides. Separately, a hidden source-code link on the .us domain points into BioBoost Labs, creating an undisclosed affiliation question. The review footprint is small and includes placeholder text, clustered positives, and challenged negatives.

Inside the full report:

  • Appendix A with per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 4 tested products
  • Delaware filings, privacy-policy captures, and Wayback evidence tying the site chronology to Liberty Products Group LLC
  • Domestic-manufacturing claim review, including address analysis and the missing facility/operator trail
  • Horizon Analytical COA review, accreditation posture, and Direct Peptides overlap evidence
  • BioBoost Labs linkage analysis from libertypeptides.us source code and Texas franchise-tax/property records
  • Trustpilot and promotion-network review covering placeholder reviews, review clustering, and coupon-aggregator artifacts

Risk assessment

  • Corporate-identity and facility-transparency risk — high: Liberty Products Group LLC formed Oct. 25, 2024 after the Dec. 5, 2023 domain launch/May 2024 site captures, is listed not in good standing in Delaware, and no domestic manufacturing facility was identified.
  • Testing-independence risk — high: Liberty COAs rely on Horizon Analytical; available materials show no ISO 17025 accreditation claim, a Direct Peptides suite-address overlap, and investor-material language that Horizon provided Direct Peptides COAs “at cost”.
  • Product-specific quality risk — high: Finnrick testing is materially weak for BPC-157 and CJC-1295 (0 pass/4 fail each; ratings 40.13% and 19.31%) while Retatrutide is mixed (3 pass/3 fail) and Semaglutide is comparatively stronger.
  • Undisclosed affiliation / control-attribution risk — medium: A hidden libertypeptides.us source-code link ties the Liberty domain to BioBoost Labs LLC, a Texas entity at a Weatherford residential address; the relationship is not publicly explained.
  • Review-integrity risk — medium: Trustpilot for libertypeptides.us showed a placeholder “Lorem Ipsum” review, clustered positive reviews, many single-review accounts, and challenged/flagged negative reviews.